Cellebrite DI Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Cellebrite DI Ltd. covers the month of November 2024, with a specific report date of November 4, 2024. The filing addresses a corporate governance event related to the Company's Business Combination Agreement rather than routine operational or financial reporting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly informational regarding a share issuance trigger and contains no financial performance data.
Material Changes
The primary material change is the occurrence of "Triggering Event III" on November 1, 2024. This event was defined as the dollar volume-weighted average price of the Company's ordinary shares being greater than or equal to $17.50 per share for a twentieth trading day within a thirty trading-day period. This follows two previous triggering events announced on August 15, 2024, and September 16, 2024.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the execution of contractual obligations under the Merger Agreement dated April 8, 2021. Pursuant to Section 3.07 of the agreement, the Company is required to issue 5,000,000 Ordinary Shares (the "Price Adjustment Shares") to each Company Shareholder on a pro-rata basis. No forward-looking guidance, risk factors, or unusual items regarding business operations were disclosed in this specific filing.
Investor Verification Checklist
- Verify the exact number of Price Adjustment Shares to be issued to individual shareholders based on their pro-rata share.
- Confirm the timeline for the issuance of the 5,000,000 Price Adjustment Shares per shareholder.
- Review the impact of this share issuance on total outstanding share count and potential dilution.
- Check for applicable withholding tax implications as noted in the Merger Agreement.